Arrowhead Pharmaceuticals, Inc. (ARWR)

Arrowhead Pharmaceuticals Stock Forecast

Stock Price Forecast

The 9 analysts with 12-month price forecasts for Arrowhead Pharmaceuticals stock have an average target of 41.44, with a low estimate of 24 and a high estimate of 80. The average target predicts an increase of 200.29% from the current stock price of 13.80.

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$24	$41.44	$38	$80
Change	+73.91%	+200.29%	+175.36%	+479.71%

* Price targets were last updated on Feb 14, 2025.

Analyst Ratings

The average analyst rating for Arrowhead Pharmaceuticals stock from 11 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Oct '24	Nov '24	Dec '24	Jan '25	Feb '25	Mar '25
Strong Buy	4	4	4	3	3	3
Buy	4	4	4	4	4	4
Hold	3	4	4	4	4	4
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	11	12	12	11	11	11

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Mayank Mamtani B. Riley Securities	B. Riley Securities	Strong Buy Reiterates $51 → $38	Strong Buy	Reiterates	$51 → $38	+175.36%	Feb 14, 2025
Patrick Trucchio HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $80	Strong Buy	Reiterates	$80	+479.71%	Feb 12, 2025
Luca Issi RBC Capital	RBC Capital	Buy Reiterates $42	Buy	Reiterates	$42	+204.35%	Feb 11, 2025
Keay Nakae Chardan Capital	Chardan Capital	Strong Buy Maintains $60	Strong Buy	Maintains	$60	+334.78%	Feb 11, 2025
Patrick Trucchio HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $80	Strong Buy	Reiterates	$80	+479.71%	Jan 23, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

159.10M

Increased by 4,380.43%

from 3.55M

Revenue Next Year

253.95M

Increased by 59.62%

from 159.10M

EPS This Year

-3.87

from -5.00

EPS Next Year

-4.05

from -3.87

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Sep 30, 2020	Sep 30, 2021	Sep 30, 2022	Sep 30, 2023	Sep 30, 2024	Sep 30, 2025	Sep 30, 2026	Sep 30, 2027
Revenue	87.99M	138.29M	243.23M	240.74M	3.55M	159.10M	253.95M	340.61M
Revenue Growth	-47.87%	57.16%	75.89%	-1.03%	-98.53%	4,380.43%	59.62%	34.12%
EPS	-0.84	-1.36	-1.67	-1.92	-5.00	-3.87	-4.05	-4.07
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	18	16	12

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	395.9M	594.0M	564.0M
Avg	159.1M	254.0M	340.6M
Low	53.9M	92.1M	203.8M

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	11,047.6%	273.3%	122.1%
Avg	4,380.4%	59.6%	34.1%
Low	1,417.9%	-42.1%	-19.7%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	1.59	-2.26	-2.89
Avg	-3.87	-4.05	-4.07
Low	-5.41	-5.31	-5.20

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.